Simon Barry J. Sells 25,000 ImmunityBio Shares in Rule 144 Plan‑Based Move, Signals Steady Confidence in High‑Growth Biotech Stock
Insider sale by Simon Barry of ImmunityBio shares signals cautious optimism, reflecting plan‑based gains while the company’s high‑growth, high‑volatility profile remains a key investor focus.
3 minutes to read